A nurse is caring for a client with cirrhosis who is scheduled to undergo a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure. What is the primary purpose of this procedure in clients with cirrhosis?

Nitroglycerin is a nitrate vasodilator commonly used for the rapid relief and prevention of angina pectoris. Sublingual tablets act quickly by relaxing vascular smooth muscle and improving myocardial oxygen supply while reducing cardiac workload. Because nitroglycerin is highly sensitive to light, heat, air, and moisture, improper storage can reduce its effectiveness. Correct storage is essential to maintain potency and ensure therapeutic action during an acute chest pain episode.

Rationale:
A. Storing nitroglycerin in an open bottle or pill organizer is inappropriate because exposure to air, moisture, and light causes the tablets to lose potency rapidly. The original tightly sealed glass container is specifically designed to protect the medication from environmental degradation. Using pill organizers increases the risk that the client will receive ineffective medication during an angina attack.

B. Nitroglycerin should be stored in a light-resistant container because the medication is highly unstable when exposed to light and air. The original dark-colored glass bottle helps preserve potency and prevents breakdown of the active ingredient. Keeping the lid tightly closed and avoiding transfer to other containers helps ensure the medication remains effective when urgently needed.

C. Refrigeration is not recommended for routine storage of sublingual nitroglycerin tablets. Extreme temperatures and moisture from refrigeration can negatively affect the medication and compromise tablet stability. The preferred storage method is at room temperature in the original light-resistant container, away from heat, humidity, and direct sunlight.

D. Nitroglycerin is not routinely discarded after one month regardless of appearance. Most recommendations advise replacing tablets approximately every 6 months after opening, depending on manufacturer guidance and storage conditions. The key concern is loss of potency rather than visible changes, so the medication should be checked based on expiration guidance rather than an arbitrary one-month rule.

Acute stroke management follows evidence-based core measures aimed at improving outcomes, reducing complications, and preventing recurrence. These measures include timely reperfusion therapy, prevention of venous thromboembolism (VTE), appropriate antithrombotic management, and patient education. Early implementation of standardized stroke protocols improves survival and functional recovery. Nursing care plays a central role in ensuring adherence to these time-sensitive and guideline-driven interventions.

Rationale:
A. Delaying rehabilitation assessments until after discharge is incorrect because early rehabilitation evaluation is an essential component of stroke care. Early mobilization and assessment help reduce complications such as contractures, pressure injuries, and functional decline. Rehabilitation planning begins during hospitalization to improve recovery outcomes.

B. Reevaluating antithrombotic therapy on hospital day 2 is appropriate because stroke management includes reassessment of antiplatelet or anticoagulant therapy based on stroke type and clinical progression. This ensures optimal prevention of recurrent cerebrovascular events while balancing bleeding risk. Adjustments are made according to diagnostic findings and patient response.

C. Documenting stroke education for the client is a core measure because patient and family education is essential for secondary prevention. Education includes risk factor modification, medication adherence, and recognition of stroke warning signs. Proper documentation ensures continuity of care and confirms that discharge teaching has been completed.

D. Increasing the dosage of anticoagulants immediately is not a core stroke measure and may be unsafe without proper evaluation. Anticoagulant therapy must be carefully individualized based on stroke type (ischemic vs hemorrhagic) and bleeding risk. Empiric dose escalation could increase the risk of intracranial hemorrhage.

E. Providing VTE prophylaxis is a key core measure because stroke clients are at high risk for immobility-related complications such as deep vein thrombosis and pulmonary embolism. Interventions may include pharmacologic prophylaxis (e.g., low-dose heparin) and mechanical devices like sequential compression devices. This reduces morbidity and mortality during hospitalization.

F. Administering thrombolytic therapy as indicated is a critical acute stroke intervention for eligible clients with ischemic stroke. Timely administration of thrombolytics such as tissue plasminogen activator (tPA) can restore cerebral perfusion and minimize neurologic damage. This treatment must be given within a strict therapeutic time window and after exclusion of hemorrhagic stroke.